NEW YORK (GenomeWeb) – Instruments manufacturer Intellicyt announced today that it is teaming up with oncology clinical lab Notable Labs to develop a predictive personalized medicine platform to help clinicians make treatment decisions for cancer patients.

Notable Labs will integrate Intellicyt's iQue Screener Plus platform into a fully automated, high-throughput lab to immune-profile phenotypic and functional endpoints of cells and secreted proteins through cell- and bead-based assays. Treatment options in order of priority will then be sent to clinicians.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.